Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the launch of a Phase I clinical trial of STP122G based on the Group’s GalNAc Factor XI Program.
Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the launch of a Phase I clinical trial of STP122G based on the Group’s GalNAc Factor XI Program.